TMCnet News
New Study Finds Active Ingredient in CUTANIX(R) Lotion Effective in Reducing Facial Redness and FlushingSAN MATEO, Calif. --(Business Wire)-- Oct. 5, 2005 -- CUTANIX(R) Topical Fades Sunburn and Relieves Itching Without a Prescription For millions of Americans suffering from facial redness and flushing due to underlying dermatologic disorders, excessive sun exposure, or persistent itching after mosquito bites, a new class of clinically proven anti-inflammatory products could provide relief. Scientific data from a study conducted by a leading dermatologist finds that Quadrinone(R) - the active ingredient in CUTANIX(R) Dramatic Relief lotion - significantly improved facial redness from rosacea in patients who used the topical lotion for 4 weeks. In the paper entitled "The Efficacy of 1% 4-ethoxybenzaldehyde (Quadrinone) in Reducing Facial Erythema" published in a recent issue of Dermatologic Surgery, lead author Zoe Diana Draelos, M.D., examined the effects of the new CUTANIX product in a pilot study of 30 people with mild to moderate facial rosacea. Twenty of the study subjects were randomly selected to receive the CUTANIX topical lotion, which they applied to their face twice daily, while the other 10 subjects in the control group only received the lotion vehicle - without Quadrinone. When determining the effectiveness of the CUTANIX lotion in reducing symptoms over four weeks, Dr. Draelos and her research team reported "that there was a statistically significant improvement in erythema (facial redness), uneven skin tone, desquamation (peeling) and overall severity of rosacea." With respect to reduction in overall severity of rosacea, results demonstrated 72% of subjects treated with the CUTANIX lotion showed some improvement in their condition, with an average improvement of 49%. In contrast, there was no statistically significant improvement in any of the five measures in the control group. Further, researchers reported that application of the topical CUTANIX formulation caused an apparent reduction in facial lesions related to rosacea. Additional clinical experience has shown CUTANIX is also effective in reducing redness due to other conditions and on other parts of the body. The product has been shown to relieve inflammation, stinging, itching and scaling and other symptoms associated with sunburn and insect bites. "We are pleased with the findings of this study that prove the benefits of CUTANIX to patients with facial redness. We are optimistic that CUTANIX products will prove to be of benefit to patients with a variety of skin conditions that involve inflammation, and may provide an attractive alternative to anti-inflammatory drugs for those who prefer such a topical alternative," says Steven L. Basta, President and CEO of BioForm Medical, Inc., which commercializes CUTANIX and other innovations for skincare. About CUTANIX BioForm Medical, Inc. is the exclusive distributor of the Cutanix product line, which was recently acquired from Cutanix Corporation. CUTANIX is available without a prescription in easy-to-use lotions formulated for all skin types. Consumers can purchase the product line online at www.cutanix.com or by calling 1-888-751-SKIN (7546). The product is also sold through dermatologists, plastic surgeons and licensed skin care professionals. About BioForm Medical, Inc. BioForm Medical, Inc. is a privately-held medical device company developing and commercializing injectable implant products for soft and hard tissue augmentation and topical preparations for dermatological conditions. The Company is dedicated to improving patients' lives by providing high quality, innovative, safe and effective medical products for use in the plastic surgery, dermatology, urology, and ENT markets. For more information, please visit the Company's website at www.bioformmedical.com. |
